Female lead at company focused on applying microbiome science to animal health
Anizome, a company focusing on the commercial application of microbiome science in animal health, has appointed Dr Ellie Virtue as its CEO.
It said that she brings extensive scientific and commercial experience in start-up human and veterinary biotech companies: "She has provided consulting and business services to early-stage human and veterinary companies where her roles have included a wide range of functions including operations, commercialisation, R&D, project management and alliance management."
Prior to taking on this CEO role, Dr Virtue was investment manager at Stonehaven Incubate, one of Anizome's founding partners, where it was her role to identify human health technologies with potential for the animal health market.
She has a Master of Applied Finance from Macquarie University and a PhD from University of Melbourne, Australia, while her PhD research on zoonotic viruses was conducted at the Australian Animal Health Laboratory. From 2011 until 2017, she worked for the animal health monoclonal antibody company, Nexvet Biopharma, where her roles encompassed research and development, operations, alliance management and business development, said Anizome.
